Media control: a case for privatization in transitional economies

The television market can be one of the most dynamic industries if country-specific regulations allow for private competitors to enter the market. The entry of competition changes the market from monopolistic to oligopolistic, which has positive performance implications for the industry. Our research analyzes the development of the Croatian TV market from the monopolistic stage to the current oligopolistic stage. Econometric models in this article aim to estimate the current trend of market concentration and its future potential. The authors’ research focusing on the industry from a market concentration perspective provides guidance for the practitioner in regard to profitable investment opportunities. They also illustrate for other transitional economies that to move toward a “free” society, media must be free from government control which will evolve rapidly once privatized. © 2016 Taylor & Francis

Additive Manufacturing für die Luft- und Raumfahrt - Von der Probenebene zu Komponenten

Overview of DLRs additive Manufacturing activities in space propulsion and satellite

Additive Manufacturing for Space Applications

Gastvorlesung im Rahmen des Masterstudiengangs "Aerospace Engineering" an der TU Darmstadt. - Definitionen additiver Fertigungsprozesse - Funktionsweise des additiven Fertigungsprozesses Laser Powder Bed Fusion (LPBF) - Charakteristische Mikrostruktureigenschaften und mechanischen Eigenschaften mittels LPBF gefertigter Bauteile - Einflussfaktoren auf die Bauteilqualität im LPBF-Prozess - Projektbeispiele aus dem DLR im Bereich LPBF für Raumfahrtanwendunge

Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

BackgroundCLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical interventions used to manage this condition.MethodsAn expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individuals were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A systematic literature review of published evidence using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance was independently and simultaneously conducted to develop key statements based upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi consensus determination process using the virtual meeting (Within3) online platform which requested experts to agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation (AGREEII) criteria.ResultsTwenty-one international experts from 7 different specialities, including a patient advocate, were identified. Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnostics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Considerations, Social Care Considerations, Pain Management, Epilepsy / Seizures, Nutritional Care Interventions, Respiratory Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one exception which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the lowest quality, and 7 represents the highest quality).ConclusionThis program provides robust evidence- and consensus-driven guidelines that can be used by all healthcare professionals involved in the management of patients with CLN2 disease and other neurodegenerative disorders. This addresses the clinical need to complement other information available